Search Results - Vacirca, JL

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Abstract OT1-02-10: A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC

    Abstract OT1-02-10: A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC by Lathrop, K, Lucas, J, Vacirca, JL, Bhat, G, Choi, MR, Naughton, M

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Abstract P5-11-07: Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

    Abstract P5-11-07: Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen by Vacirca, JL, Papai, Z, Horvath, Z, Makharadze, R, Reddy, G, Song, T, Koli, P, Schwartzberg, LS

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract P5-11-08: Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

    Abstract P5-11-08: Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen by Vacirca, JL, Papai, Z, Agajanian, R, Horvath, Z, Makharadze, R, Ibrahim, E, Koli, P, Reddy, G, Tedesco, KL, McGregor, K, Schwartzberg, LS

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Abstract OT1-01-11: Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)

    Abstract OT1-01-11: Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage... by Schwartzberg, LS, Bharadwaj, J, Peguero, JA, Vacirca, JL, Ibrahim, EN, Bhat, G, Choi, MR, McGregor, K, Agajanian, R

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study

    Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study by Vacirca, JL, Agajanian, R, Papai, Z, Horvath, Z, Makharadze, R, Ibrahim, EN, Choi, MR, Song, T, Tedesco, KL, McGregor, K, Schwartzberg, LS

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment

    Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment by Domenyuk, V, Gatalica, Z, Santhanam, R, Wei, X, Stark, A, Kennedy, P, Toussaint, B, Levenberg, S, Wang, R, Xiao, N, Greil, R, Rinnerthaler, G, Gampenrieder, S, Heimberger, AB, Berry, DJ, Barker, A, Demetri, GD, Quackenbush, J, Marshall, JL, Poste, G, Vacirca, JL, Vidal, GA, Schwartzberg, LS, Halbert, DD, Voss, A, Miglarese, MR, Famulok, M, Mayer, G, Spetzler, D

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Abstract OT3-02-13: Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)

    Abstract OT3-02-13: Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage brea... by Schwartzberg, L, Vacirca, JL, Hager, SJ, Adoo, CS, Ibrahim, EN, Bhat, G, Choi, MR, Allen, LF, Tedesco, KL, Agajanian, R

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Abstract P1-10-05: Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC)

    Abstract P1-10-05: Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with b... by Vacirca, JL, Chan, A, Mezei, K, Adoo, CS, Papai, Z, McGregor, K, Okera, M, Horvath, Z, Landherr, L, Hanslik, J, Hager, SJ, Ibrahim, EN, Ghazal, H, Rostom, M, Bhat, G, Choi, MR, Allen, LF, Tedesco, KL, Agajanian, R, Lang, I

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: